268 related articles for article (PubMed ID: 18974847)
1. Raft-dependent endocytosis of autocrine motility factor/phosphoglucose isomerase: a potential drug delivery route for tumor cells.
Kojic LD; Wiseman SM; Ghaidi F; Joshi B; Nedev H; Saragovi HU; Nabi IR
PLoS One; 2008; 3(10):e3597. PubMed ID: 18974847
[TBL] [Abstract][Full Text] [Related]
2. Raft-dependent endocytosis of autocrine motility factor is phosphatidylinositol 3-kinase-dependent in breast carcinoma cells.
Kojic LD; Joshi B; Lajoie P; Le PU; Cox ME; Turbin DA; Wiseman SM; Nabi IR
J Biol Chem; 2007 Oct; 282(40):29305-13. PubMed ID: 17690101
[TBL] [Abstract][Full Text] [Related]
3. Raft endocytosis of AMF regulates mitochondrial dynamics through Rac1 signaling and the Gp78 ubiquitin ligase.
Shankar J; Kojic LD; St-Pierre P; Wang PT; Fu M; Joshi B; Nabi IR
J Cell Sci; 2013 Aug; 126(Pt 15):3295-304. PubMed ID: 23690547
[TBL] [Abstract][Full Text] [Related]
4. The complex biology of autocrine motility factor/phosphoglucose isomerase (AMF/PGI) and its receptor, the gp78/AMFR E3 ubiquitin ligase.
Fairbank M; St-Pierre P; Nabi IR
Mol Biosyst; 2009 Aug; 5(8):793-801. PubMed ID: 19603112
[TBL] [Abstract][Full Text] [Related]
5. Autocrine motility factor/phosphoglucose isomerase regulates ER stress and cell death through control of ER calcium release.
Fu M; Li L; Albrecht T; Johnson JD; Kojic LD; Nabi IR
Cell Death Differ; 2011 Jun; 18(6):1057-70. PubMed ID: 21252914
[TBL] [Abstract][Full Text] [Related]
6. Regulation of phosphoglucose isomerase/autocrine motility factor activities by the poly(ADP-ribose) polymerase family-14.
Yanagawa T; Funasaka T; Tsutsumi S; Hu H; Watanabe H; Raz A
Cancer Res; 2007 Sep; 67(18):8682-9. PubMed ID: 17875708
[TBL] [Abstract][Full Text] [Related]
7. Species specificity of the cytokine function of phosphoglucose isomerase.
Amraei M; Nabi IR
FEBS Lett; 2002 Aug; 525(1-3):151-5. PubMed ID: 12163179
[TBL] [Abstract][Full Text] [Related]
8. pH-specific sequestration of phosphoglucose isomerase/autocrine motility factor by fibronectin and heparan sulphate.
Lagana A; Goetz JG; Y N; Altschuler Y; Nabi IR
J Cell Sci; 2005 Sep; 118(Pt 18):4175-85. PubMed ID: 16141236
[TBL] [Abstract][Full Text] [Related]
9. Autocrine motility factor induces differential 12-lipoxygenase expression and activity in high- and low-metastatic K1735 melanoma cell variants.
Silletti S; Timar J; Honn KV; Raz A
Cancer Res; 1994 Nov; 54(22):5752-6. PubMed ID: 7954394
[TBL] [Abstract][Full Text] [Related]
10. Novel roles of the autocrine motility factor/phosphoglucose isomerase in tumor malignancy.
Yanagawa T; Funasaka T; Tsutsumi S; Watanabe H; Raz A
Endocr Relat Cancer; 2004 Dec; 11(4):749-59. PubMed ID: 15613449
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of the autocrine motility factor/phosphoglucose isomerase induces transformation and survival of NIH-3T3 fibroblasts.
Tsutsumi S; Hogan V; Nabi IR; Raz A
Cancer Res; 2003 Jan; 63(1):242-9. PubMed ID: 12517804
[TBL] [Abstract][Full Text] [Related]
12. Suppression of AMF/PGI-mediated tumorigenic activities by ursolic acid in cultured hepatoma cells and in a mouse model.
Shih WL; Yu FL; Chang CD; Liao MH; Wu HY; Lin PY
Mol Carcinog; 2013 Oct; 52(10):800-12. PubMed ID: 22549898
[TBL] [Abstract][Full Text] [Related]
13. Suppression of melanoma cell motility factor receptor expression by retinoic acid.
Lotan R; Amos B; Watanabe H; Raz A
Cancer Res; 1992 Sep; 52(18):4878-84. PubMed ID: 1325286
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of phosphoglucose isomerase/autocrine motility factor results in mesenchymal-to-epithelial transition of human lung fibrosarcoma cells.
Funasaka T; Hu H; Yanagawa T; Hogan V; Raz A
Cancer Res; 2007 May; 67(9):4236-43. PubMed ID: 17483335
[TBL] [Abstract][Full Text] [Related]
15. [The role of autocrine motility factor receptor in metastasis].
Watanabe H; Chigira M; Raz A
Gan To Kagaku Ryoho; 1993 Feb; 20(3):405-9. PubMed ID: 8382466
[TBL] [Abstract][Full Text] [Related]
16. Clathrin-mediated endocytosis and recycling of autocrine motility factor receptor to fibronectin fibrils is a limiting factor for NIH-3T3 cell motility.
Le PU; Benlimame N; Lagana A; Raz A; Nabi IR
J Cell Sci; 2000 Sep; 113 ( Pt 18)():3227-40. PubMed ID: 10954421
[TBL] [Abstract][Full Text] [Related]
17. Silencing of phosphoglucose isomerase/autocrine motility factor decreases U87 human glioblastoma cell migration.
Li Y; Wei Z; Dong B; Lian Z; Xu Y
Int J Mol Med; 2016 Apr; 37(4):998-1004. PubMed ID: 26936801
[TBL] [Abstract][Full Text] [Related]
18. Expression and function of the AMF receptor by human melanoma in experimental and clinical systems.
Tímár J; Rásó E; Döme B; Ladányi A; Bánfalvi T; Gilde K; Raz A
Clin Exp Metastasis; 2002; 19(3):225-32. PubMed ID: 12067203
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor binding protein-3 interacts with autocrine motility factor/phosphoglucose isomerase (AMF/PGI) and inhibits the AMF/PGI function.
Mishra S; Raz A; Murphy LJ
Cancer Res; 2004 Apr; 64(7):2516-22. PubMed ID: 15059907
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of phosphoglucose isomerase/autocrine motility factor enhances gensenoside Rh2 pharmacological action on leukemia KG1α cells.
You ZM; Zhao L; Xia J; Wei Q; Liu YM; Liu XY; Chen DL; Li J
Asian Pac J Cancer Prev; 2014; 15(3):1099-104. PubMed ID: 24606425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
